SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE.

The agreement was formalized during the 2023 Inspire2Live Annual Congress held on November 29^th and 30^th in Amsterdam, the Netherlands. Representatives from 27 countries who are devoted to bringing the patient voice to the table joined this year's congress on the theme of "If about us, not without us". SeekIn's founder and CEO, Dr. Mao Mao, delivered an inspiring speech, shedding light on the company's cutting-edge cancer detection tests, while emphasizing the importance of early detection and improved patient outcomes. The OncoSeek test focuses on screening nine common cancer types with seven protein tumor markers (PTMs) whereas SeekInCare, SeekInCure and SeekInClarity are designed for cancer early detection, recurrence monitoring and treatment monitoring respectively incorporating shallow whole genomic sequencing and PTMs. Participants at the Inspire2Live congress were given the opportunity to take an OncoSeek test.

Commenting on the significance of this collaboration, Dr. Mao Mao stated, "We are thrilled to join forces with Inspire2Live and Oncolnv, two patient-centric organizations committed to revolutionizing cancer detection and treatment. With their extensive network and dedication to the cause, we can better serve cancer patients globally, providing them with advanced detection technologies and empowering healthcare providers with the tools that they need to fight this devastating disease."

Inspire2Live's founder, Mr. Peter Kapitein, expressed his excitement about the partnership, stating, "This collaboration aligns perfectly with our organization's vision of a world where access to quality cancer care is universal. Together, we can make a real difference in the lives of countless patients around the globe." Oncolnv is at the forefront of clinical settings and pays considerable attention to cancer screening, early diagnosis and personalized monitoring with patient care at the core. By partnering with SeekIn, Oncolnv gains valuable access to comprehensive cancer detection solutions for diverse health care systems, helping to bridge global disparities in cancer care.

In addition, this collaboration opens doors to future research initiatives, creating opportunities for joint clinical trials, information exchange, and collaborative development of innovative cancer detection methodologies. By leveraging the expertise of both organizations, this collaborative effort aims to improve patient outcomes and increase survival rates.

As SeekIn expands its global footprint, its commitment to research, innovation, and patient-centric care remains unwavering. The collaboration between SeekIn and Oncolnv brings together the collective expertise and resources needed to address the global cancer burden comprehensively.